For Research Purposes Only. This page summarizes published preclinical and clinical research. It does not constitute medical advice and is not a recommendation for human use. Always consult a qualified healthcare professional.
CJC-1295 + Ipamorelin
The most widely researched GH secretagogue stack. CJC-1295 amplifies GHRH signaling; Ipamorelin selectively triggers a clean GH pulse. Complementary mechanisms, commonly used together.
Overview
CJC-1295 and Ipamorelin are paired as a growth hormone secretagogue stack because they stimulate GH release through two distinct, non-overlapping receptor pathways. CJC-1295 is an analogue of growth hormone-releasing hormone (GHRH) and acts at the GHRH receptor on pituitary somatotrophs, increasing the amplitude of GH pulses. Ipamorelin acts at the ghrelin receptor (GHSR-1a), independently triggering GH secretion through a separate signaling pathway. When administered together, they engage both arms of the pituitary GH regulatory axis, producing a synergistic response greater than either compound alone.
CJC-1295 (the DAC version) is modified with a Drug Affinity Complex — a side-chain that enables covalent binding to circulating albumin. This modification dramatically extends the plasma half-life from approximately 30 minutes (seen with Mod GRF 1-29, also called CJC-1295 without DAC) to 6–8 days. A Phase I/II study by Ionescu and Frohman (The Journal of Clinical Endocrinology & Metabolism, 2006) demonstrated dose-dependent, sustained increases in mean GH and IGF-1 concentrations following single injections of CJC-1295 DAC in healthy adults — a notable finding for a research compound. The two variants (with and without DAC) are different compounds with different half-lives, different dosing schedules, and different GH release patterns, and are not interchangeable.
Ipamorelin (originally designated CP-424,391 by Pfizer) is a pentapeptide that binds GHSR-1a with high selectivity. Its defining characteristic relative to older growth hormone-releasing peptides (GHRP-2, GHRP-6, hexarelin) is a highly selective action profile — it stimulates GH release with minimal co-stimulation of ACTH, cortisol, or prolactin. This selectivity makes it the preferred research tool when isolating GH-specific effects. Ipamorelin advanced to Phase II clinical trials for postoperative gastrointestinal ileus (by Helsinn Therapeutics), generating human safety and pharmacokinetic data for the compound, though not for GH-stimulation applications specifically.
Research Status
Ionescu and Frohman (J Clin Endocrinol Metab, 2006): Phase I CJC-1295 data demonstrating sustained GH/IGF-1 elevation over 2 weeks following single injection. Lall et al. characterized ipamorelin's selectivity vs. GHRP-2 and GHRP-6. Svensson et al. published pituitary binding and selectivity data for ipamorelin. Helsinn Phase II trial data for ulimorelin (TZP-101, same compound) are available at clinicaltrials.gov.
Common Research Protocols
Dose ranges are from published Phase I/II data and community-reported protocols. The CJC-1295 dosing differs substantially between the DAC (long-acting) and no-DAC (short-acting) variants. Confirm which form you have before referencing any protocol. This is for educational reference only and is not a recommendation for human use.
Storage & Handling
Store lyophilized peptides at −20°C. Once reconstituted, refrigerate at 4°C and use within 28–30 days. If purchasing as a blend, the stability characteristics of the combined formulation depend on the specific product.
What to Look for When Buying
Confirm which CJC-1295 variant you are purchasing: CJC-1295 with DAC (long-acting, ~7-day half-life) vs. CJC-1295 without DAC / Mod GRF 1-29 (short-acting, ~30-minute half-life). These are different compounds with different dosing schedules and are not interchangeable.
Both CJC-1295 and Ipamorelin are commonly sold as pre-mixed blend vials in addition to being sold separately. Blends are convenient but make it harder to verify the ratio and concentration of each component independently.
Ipamorelin is a pentapeptide (5 amino acids) and is relatively straightforward to synthesize — purity tends to be higher across vendors compared to more complex peptides. CJC-1295 (with DAC) is more structurally complex due to the DAC modification and warrants closer attention to purity data.
Finnrick has tested both CJC-1295 and Ipamorelin from multiple vendors. Check purity scores for each compound independently — a vendor may perform well on one and poorly on the other.
When comparing blended CJC-1295 + Ipamorelin vials, confirm the stated ratio of each peptide and whether the COA covers both components or only one.
Compare Vendor Pricing
PepVendors tracks live pricing for CJC-1295 + Ipamorelin across multiple vendors, updated weekly. Compare price per mg, available sizes, and purity data side by side.
Compare CJC-1295 + Ipamorelin prices →Third-Party Purity Data
Full data at finnrick.com →Independent HPLC test results from Finnrick Analytics. Purity values are averages across multiple samples. Check the Finnrick vendor page for batch-level detail.
For Research Purposes Only — Not Medical Advice. The information on this page is compiled from published peer-reviewed research, publicly available clinical trial data, and independent third-party testing results. It is intended solely as an educational reference for researchers.
Nothing on this page constitutes medical advice, a diagnosis, or a treatment recommendation. Peptides listed as research chemicals are not approved for human consumption unless explicitly noted as FDA-approved pharmaceuticals. PepVendors is a price comparison and information platform — we do not manufacture, sell, or distribute any compounds. Always consult a qualified and licensed healthcare professional before considering any compound for personal use.